Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on...

Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine. Neutralizing and specific HPV-binding serum antibodies were measured at baseline and 12 months after the first vaccine dose. Presence of neutralizing and binding antibodies had good agreement (average Kappa for HPV types 6, 11, 16, 18...

Last month’s US FDA and WHO approval of CervarixTM, GlaxoSmithKline’s (GSK [London, UK]) vaccine against human papillomavirus (HPV) types 16 and 18 [101], boosted GSK’s position in the global HPV vaccine market. Gardasil, Merck’s vaccine against HPV types 6, 11, 16 and 18, obtained US FDA and WHO approvals in 2006. US FDA rejection of Cervarix 2 years ago, together with Cervarix’s lack of prote...

Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25.

Pre-adolescent girls (9-15years) have the option of receiving a two dose HPV vaccine series at either a six month or one year interval to provide protection from HPV 16, the most prevalent type associated with cervical cancers, as well as several other less prevalent types. This series of vaccinations is highly likely to protect her from HPV infection until she enters the routine screening prog...

conclusions the results of this meta-analysis showed that gardasil and cervarix vaccines are highly effective against cervical cancer. according to the point that approximately 50% of cervical cancers and human carcinogenicity are related to hpv-16 infection, the bivalent hpv vaccine might have protective effects against hpv-16 cin2-3 lesion and cervical cancer. results by combining the results...

Globally, about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection. A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples. The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions. This phase I trial (NCT0054...